Benzinga · Sep 28, 2026
Azitra Enters Sales Agreement With A.G.P. For Common Stock Offering; May Offer Common Stock Up To $3.50M Through A.G.P.
-SEC Filing
AZ
AMEX · AZTR
Azitra, Inc.
Healthcare · Biotechnology
$0.13
Up+$0.00 (+1.54%)
Updated Oct 8, 2026, 12:32 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.72M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- $0.10 – $1.09
- Volume
- 413.23K
- Avg. volume
- 2.58M
Price performance · AZTR
AZTR price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
AZTR closed at $0.13 after 20 trading sessions, down 27.01% for the selected period.
- Last close
- $0.13
- Period change
- -27.01%
- Period low
- $0.13
- Period high
- $0.18
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $0.1399 | $0.1399 | $0.13 | $0.13 | 413.23K |
| Oct 5, 2026 | $0.138 | $0.1398 | $0.1298 | $0.1366 | 622.88K |
| Oct 2, 2026 | $0.1337 | $0.1383 | $0.1297 | $0.132 | 825.84K |
| Oct 1, 2026 | $0.139 | $0.1468 | $0.1231 | $0.1285 | 1.43M |
| Sep 30, 2026 | $0.1338 | $0.1388 | $0.1324 | $0.1376 | 611.02K |
| Sep 29, 2026 | $0.1644 | $0.1668 | $0.1241 | $0.1306 | 3.21M |
| Sep 28, 2026 | $0.17 | $0.175 | $0.1634 | $0.1695 | 617.08K |
| Sep 25, 2026 | $0.161 | $0.1693 | $0.161 | $0.1678 | 159.31K |
| Sep 24, 2026 | $0.1663 | $0.168 | $0.1586 | $0.167 | 605.97K |
| Sep 23, 2026 | $0.17 | $0.1749 | $0.1649 | $0.1655 | 849.46K |
| Sep 22, 2026 | $0.1724 | $0.1743 | $0.1664 | $0.1706 | 296.47K |
| Sep 21, 2026 | $0.1773 | $0.1773 | $0.167 | $0.171 | 620.04K |
| Sep 18, 2026 | $0.1812 | $0.1812 | $0.17 | $0.174 | 1.12M |
| Sep 17, 2026 | $0.162 | $0.18 | $0.162 | $0.178 | 568.47K |
| Sep 16, 2026 | $0.1757 | $0.1757 | $0.161 | $0.1624 | 1.12M |
| Sep 15, 2026 | $0.1778 | $0.179 | $0.171 | $0.171 | 476.27K |
| Sep 14, 2026 | $0.185 | $0.1914 | $0.1755 | $0.1755 | 1.3M |
| Sep 11, 2026 | $0.1823 | $0.1853 | $0.177 | $0.1781 | 300.4K |
| Sep 10, 2026 | $0.1779 | $0.1878 | $0.1733 | $0.1801 | 570.11K |
| Sep 9, 2026 | $0.1709 | $0.1825 | $0.1685 | $0.1781 | 607.23K |
Latest AZTR news
The latest Smart Investors Daily articles mentioning AZTR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AZTR research
Overview
Company profile and research snapshot.
Company profile
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $2.75
- Implied upside
- —
- Analysts
- 7
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2025 | Maxim Group | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 28, 2026
AZTR: Updated Valuation Reflects Cosmetic and EGFRi Rash Programs
By John Vandermosten, CFA NYSE: AZTR READ THE FULL AZTR RESEARCH REPORT Azitra, Inc. (NYSE: AZTR) reported second quarter 2026 financial and operational results on August 12 th , 2026, and provided a business update. Year to date 2026, Azitra has raised gross proceeds of approximately $10.5 million in capital that will support the launch of a new initiative in cosmetics and cosmeceuticals along
Yahoo · Sep 8, 2026
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that Travis Whitfill Ph.D., MPH, Azitra's Co-founder and Chief Operating Officer, will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, to be held from September 14-16, 2026, in New York City.
Benzinga · Aug 21, 2026
Azitra Regains NYSE American Compliance
Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
